Fig. 3From: Qualitative interviews of patients with COPD and muscle weakness enrolled in a clinical trial evaluating a new anabolic treatment: patient perspectives of disease experience, trial participation and outcome assessmentsOverview of (A) symptoms and (B) functional limitationsa. aReported by participants during the 60-minute (n = 32) and 15-minute exit interviews (n = 35) at the start of the trial. The remaining participants were either not questioned regarding the relevant symptom or limitation, or did not spontaneously mention it during the interviewBack to article page